---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209745"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:55:57.910226+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon posts Q2 2023 net loss of $13.9M; cash $151M funds ops into 2025

## Summary
- Net loss $13.9M vs $5.8M in Q2 2022; R&D expenses $10.5M, up from $4.1M.
- Cash, equivalents and marketable securities $151.0M as of June 30, 2023.
- Registrational-intent Phase 2 trial of ACR-368 enrolling; initial data expected H2 2023.
- FDA granted two Fast Track designations for ACR-368 in OncoSignature-positive ovarian and endometrial cancers.
- Appointed Charles Baum to board and Adam Levy as SVP IR and corporate affairs.

## SEC filing metadata
- accession: 0001193125-23-209745
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/0001193125-23-209745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/d337383d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209745
- JSON: https://secwatch.observer/filing/0001193125-23-209745.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209745.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $13.9 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: $13.9 million
  - Result: reported results
  source text: Net loss for the quarter ended June 30, 2023 was $13.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/0001193125-23-209745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.